If a reduction in dysferlin-expression would occur in dysferlinopathy patients, then it would affect patients with residual or partially functional dysferlin protein more than patients without any protein. This evidence concerns the gene DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin.